Printer Friendly

CISTRON ANNOUNCES INCREASED SECOND QUARTER SALES

 CISTRON ANNOUNCES INCREASED SECOND QUARTER SALES
 PINE BROOK, N.J., March 19 /PRNewswire/ -- Cistron Biotechnology,


Inc., today reported increased sales for its second quarter ended Dec. 31, 1991.
 Second quarter sales were $240,118, up from $231,427 in the comparable quarter last year. The company had a net loss of $43,276 versus a net loss of $10,115 in last year's second quarter.
 The increased loss is the result of higher administrative, marketing and occupancy expenses and higher non-cash expenses comprised of the final amortization of deferred financing costs and a tax benefit recorded in 1990 which did not recur in 1991.
 Sales for the first six months of fiscal 1992 were $506,012 compared with $526,499 for the same period last year. The company had a net loss of $22,984 in the first six months versus net income of $34,029 for the comparable 1991 period.
 Cistron's primary product area is immune response regulators, known as lymphokines. The company manufactures and sells lymphokine assay kits to pharmaceutical companies and academic institutions in the United States, Europe and the Far East for cancer, arthritis and other autoimmune disease research.
 The company is currently expanding its product line and has initiated research on IL-1 beta inhibitors. An effective inhibitor would reduce inflammation and possible bone and cartilage deterioration in such autoimmune diseases as rheumatoid arthritis and lupus.
 CISTRON BIOTECHNOLOGY, INC., FINANCIAL SUMMARY
 Three months ended Dec. 31 1991 1990
 Net sales $240,118 $231,427
 Earnings (loss) before
 income taxes (43,276) (16,912)
 Income taxes (benefit) -- (6,797)
 Net income (loss) (43,276) (10,115)
 Net income (loss) per share -- --
 Weighted average number
 of shares outstanding 27,208,994 25,017,191
 Six months ended Dec. 31 1991 1990
 Net sales $506,012 $526,499
 Earnings (loss) before
 income taxes (22,984) 34,029
 Income taxes -- 13,675
 Extraordinary credit - tax
 loss carry forward -- 13,675
 Net income (loss) (22,984) 34,029
 Net income (loss) per share -- --
 Weighted average number
 of shares outstanding 26,448,221 25,017,191
 -0- 3/19/92
 /CONTACT: Harold Smith of Hal Smith Associates, 201-305-0244, for Cistron Biotechnology/ CO: Cistron Biotechnology, Inc. ST: New Jersey IN: MTC SU: ERN


TQ-OS -- NY006 -- 9507 03/19/92 08:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 19, 1992
Words:379
Previous Article:FDA ACCEPTS SUMMIT'S APPLICATION FOR APPROVAL TO COMMERCIALLY MARKET EXCIMER LASER SYSTEM FOR THERAPEUTIC APPLICATIONS
Next Article:QUAL-MED INC. AND FOUNDATION HEALTH CORP. SETTLE LITIGATION
Topics:


Related Articles
CISTRON REPORTS A PROFIT FOR FISCAL YEAR
CISTRON ANNOUNCES INCREASED THIRD QUARTER EARNINGS AND SALES
MEDAMICUS ANNOUNCES SECOND QUARTER RESULTS
CISTRON BIOTECHNOLOGY REPORTS SALES INCREASE FOR SECOND QUARTER AND SIX MONTHS
CISTRON INCREASES SALES AND REDUCES LOSS IN NINE MONTHS
CISTRON ANNOUNCES RESULTS FOR FISCAL 1994
CISTRON ANNOUNCES RESULTS FOR FIRST QUARTER
Cistron Biotechnology Reports 3rd Quarter Results
Moore Medical Announces Second Quarter Results
BIOMET 2ND QTR FISCAL 2008 NET SALES INCREASED 11%.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters